FibroBiologics, Inc. FBLG
We are a clinical-stage biotechnology company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including wound healing, multiple sclerosis, or MS, degenerative disc disease, psoriasis, certain cancers, and potential human longevity applications including thymic involution reversal using a thymic organoid. Our most advanced product candidates are CYWC628, CYPS317, CYMS101 and CybroCellTM.
We were formed in April 2021 as a Texas limited liability company under the name FibroBiologics, LLC, and converted to a Delaware corporation in December 2021 under the name Fibrobiologics, Inc. On April 12, 2023, we changed our name to FibroBiologics, Inc. In connection with our formation, we issued shares of our Series A Preferred Stock, or the Series A Preferred Stock, to our then parent, SpinalCyte LLC (d/b/a FibroGenesis), or FibroGenesis, in return for rights to certain intellectual property through a patent assignment agreement, or the Patent Assignment Agreement, and an intellectual property cross-licensing agreement, or the Intellectual Property Cross-License Agreement. Developing the intellectual property obtained from FibroGenesis was the basis for our formation. Prior to our inception, preclinical research and development related to the transferred intellectual property took place under the name FibroGenesis.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D | $7.4M | $4.5M | $2.4M | $1.1M | — |
| SG&A | $9.2M | $9.2M | $6.5M | $3.3M | — |
| Total operating expenses | $16.6M | $13.7M | $8.9M | $4.5M | — |
| Operating income | -$16.6M | -$13.7M | -$8.9M | -$4.5M | — |
| Interest expense | $200.0K | — | $147.0K | $654.0K | — |
| Pre-tax income | -$18.6M | -$11.2M | -$16.5M | -$5.1M | — |
| Income tax | $0 | $0 | $0 | $0 | — |
| Net income | -$18.6M | -$11.2M | -$16.5M | -$5.1M | — |
| EPS, basic | -0.42 | -0.34 | -0.68 | -0.18 | — |
| EPS, diluted | -0.42 | -0.34 | -0.68 | -0.18 | — |
| Shares, diluted (wtd. avg.) | 44.7M | 32.9M | 28.2M | 28.2M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash and equivalents | $4.9M | $14.0M | $9.2M | $2.3M | $407.0K |
| Receivables | — | — | — | $300.0K | — |
| Total current assets | $6.3M | $14.2M | $9.2M | $2.6M | — |
| Property, plant and equipment | $842.0K | $824.0K | $797.0K | — | — |
| Total assets | $9.6M | $16.4M | $11.8M | $4.8M | — |
| Accounts payable | $945.0K | $2.7M | $1.4M | $758.0K | — |
| Short-term debt | — | — | — | $300.0K | — |
| Total current liabilities | $1.8M | $12.7M | $9.2M | $7.1M | — |
| Total liabilities | $3.5M | $13.7M | $10.6M | $8.8M | — |
| Retained earnings | -$54.2M | -$35.5M | -$24.4M | -$7.9M | — |
| Total equity | $6.2M | $2.7M | $1.3M | -$4.0M | -$1.3M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$16.4M | -$11.9M | -$6.4M | -$4.1M | — |
| Depreciation and amortisation | $244.0K | $157.0K | $47.0K | — | — |
| Stock-based compensation | $2.7M | $2.2M | $1.8M | $265.0K | — |
| Capital expenditure | $262.0K | $184.0K | $495.0K | — | — |
| Investing cash flow | -$262.0K | -$184.0K | -$495.0K | — | — |
| Financing cash flow | $7.6M | $16.9M | $13.8M | $5.9M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-106216.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Net income | — | -$5.1M | -$16.5M | -$11.2M | -$18.6M |
Recent filings and events
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
- Officer or director change Item 5.02
- Regulation FD disclosure Item 7.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Regulation FD disclosure Item 7.01
- Officer or director change Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Material agreement signed Item 1.01
- Officer or director change Item 5.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |